Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.

ABSTRACT:

Background and objectives

The glucagon-like peptide-1 receptor agonist liraglutide demonstrated cardiovascular and kidney benefits in the LEADER trial, particularly in participants with CKD.

Design, setting, participants, & measurements

This post hoc analysis evaluated the safety of liraglutide treatment in patients with CKD in LEADER. Overall, 9340 patients were randomized to liraglutide or placebo, both in addition to standard of care. Of those, 2158 patients had CKD versus 7182 without CKD (defined as eGFR <60 versus ≥60 ml/min per 1.73 m², respectively); 966 patients had macroalbuminuria and 2456 had microalbuminuria (urine albumin-creatinine ratio >300 mg/g and ≥30 to ≤300 mg/g, respectively). At baseline, the mean eGFR in patients with CKD was 46±11 m

SUBMITTER: Mann JFE 

PROVIDER: S-EPMC7133133 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature